Chikungunya virus structural envelope proteins (CHIKV envelope proteins)

The Chikungunya virus (CHIKV) structural envelope proteins, comprising E1, E2, and E3, are the primary components of the viral spike complex and are essential for the virus's ability to infect host cells (UniProt, NIH). E2 is responsible for receptor binding, interacting with host factors such as Matrix Remodeling-Associated Protein 8 (Mxra8), while E1 is a class II fusion protein that mediates the fusion of the viral and host membranes (NIH, ResearchGate). These proteins are the dominant targets for neutralizing antibodies and are utilized as the primary antigens in various vaccine platforms, including live-attenuated, virus-like particle (VLP), and mRNA-based candidates (Wikipedia, NIH). For instance, the vaccines Ixchiq and Vimkunya are designed to elicit protective immunity by targeting these structural components (Wikipedia, Drugs.com). In addition to vaccines, monoclonal antibodies targeting the E2 protein are being developed as therapeutic agents to neutralize the virus and alleviate the debilitating joint pain and fever associated with Chikungunya infection (NIH, ResearchGate). However, therapeutic development faces challenges such as vaccine-induced reactogenicity and safety concerns regarding chikungunya-like illness in recipients, which has impacted the regulatory status of some products (Drugs.com). The theoretical risk of antibody-dependent enhancement (ADE) also remains a consideration in the design of envelope-targeted therapies (NIH).

Other names

Chikungunya virus envelope glycoproteinsCHIKV E1/E2/E3 complexChikungunya virus spike proteinsCHIKV structural proteinsChikungunya virus envelope protein

Vaccines and monoclonal antibodies targeting these proteins work by inducing or providing neutralizing antibodies that bind to the E2 protein to block receptor attachment or to the E1 protein to inhibit pH-dependent membrane fusion, thereby preventing viral entry and subsequent replication (NIH, Wikipedia).